1,350 reports of this reaction
5.8% of all BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE reports
#2 most reported adverse reaction
DEVICE DELIVERY SYSTEM ISSUE is the #2 most commonly reported adverse reaction for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,350 FDA adverse event reports linking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE to DEVICE DELIVERY SYSTEM ISSUE. This represents approximately 5.8% of all 23,211 adverse event reports for this drug.
Patients taking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE who experience device delivery system issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEVICE DELIVERY SYSTEM ISSUE is moderately reported among BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE users, representing a notable but not dominant share of adverse events.
In addition to device delivery system issue, the following adverse reactions have been reported for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE:
The following drugs have also been linked to device delivery system issue in FDA adverse event reports:
DEVICE DELIVERY SYSTEM ISSUE has been reported as an adverse event in 1,350 FDA reports for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEVICE DELIVERY SYSTEM ISSUE accounts for approximately 5.8% of all adverse event reports for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, making it one of the most commonly reported side effect.
If you experience device delivery system issue while taking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.